64 results about "Endometrial receptivity" patented technology

The invention discloses a traditional Chinese medicine composition for treating dysmenorrhea due to corpus luteum insufficiency and its preparation method and application. ~120 parts, 5~30 parts of cinnamon, 10~60 parts of antler slices, 15~90 parts of Chinese yam, 15~90 parts of Cuscuta seed, 10~60 parts of paeonol, 10~60 parts of salvia miltiorrhiza, 10~60 parts of trigonum and curcuma 10 to 60 parts. The present invention screens and obtains prescriptions through a large number of experiments. The experimental results show that the traditional Chinese medicine composition can reduce the degree of dysmenorrhea, reduce VAS scores, improve dysmenorrhea symptoms, TCM symptoms, and BBT curves; and can reduce PGF secreted by endometrium. 2α , ET secreted by vascular endothelial cells, serum PAF, increase serum LXA4 content; can regulate the level of sex hormones in the mid-luteal phase, improve ovarian and uterine artery blood flow, endometrial receptivity, and finally improve luteal function and relieve uterine ischemia and hypoxia , relieve pain, have a good effect on treating dysmenorrhea, and have no toxic and side effects, and the medicine is safe and reliable.

The invention relates to a kidney-tonifying fetus-developing traditional Chinese medicine composition and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw material herbs: radix rehmanniae praeparata, radix astragali, fructus ligustri lucidi, radix ophiopogonis, radix paeoniae alba, radix codonopsis, rhizoma cyperi, semen cuscutae, angelica sinensis, fructus psoraleae, salviae miltiorrhizae and radix glycyrrhizae. The invention further provides application of the traditional Chinese medicine composition. The kidney-tonifying fetus-developing traditional Chinese medicine composition has the following advantages: the estrogen level of a patient with kidney qi deficiency in the decorporation stage is remarkably improved, and more retrieved oocytes, fertilized oocytes, developed embryos and high-quality embryos are obtained; expression of endometrial vascular endothelial growth factors is remarkably improved, endometrial blood flow parameters PI and RI of the patient with kidney qi deficiency are reduced, blood perfusion is increased, and further, the endometrial recepyivity of the patient isimproved; and the embryo transfer rate can be remarkably increased, and the kidney-tonifying fetus-developing traditional Chinese medicine composition tends to increase the clinical pregnancy rate, implantation rate and persistent pregnancy rate.

The invention discloses a miRNA marker for auxiliary diagnosis of endometrial receptivity, including hsa-miR-16-2-3p, hsa-miR-92b-5p, hsa-miR-130a-3p, has-miR-3p 9024-3p miRNA and primers thereof; the present invention also provides an application of miRNA markers for auxiliary diagnosis of endometrial receptivity, which is characterized in that: comprising the following steps: S1 collecting maternal blood and preparing supernatant; S2 Process and classify the crude miRNA in the spin column filter tube; S3 prepare the miRNA sample; S4 use the kit to synthesize cDNA from the miRNA, perform PCR amplification system and program, and obtain the miRNA content data; S5 construct the CT content curve, Determination of different miRNA contents in different periods; the beneficial effect of the present invention is that by limiting the miRNA and its primers, and using the four primers after specific screening as the detection basis, the rapid and accurate identification of the endometrial receptivity period can be realized.

The invention belongs to the field of biomedicine and discloses a combination of gene markers for evaluating endometrium receptivity. The invention provides a nucleic acid composition, including DNA and RNA corresponding to 515 endometrial receptivity-related characteristic genes. The invention also discloses the application of the above gene marker combination in preparing endometrial receptivity testing products. The present invention includes a molecular biological method for evaluating endometrial receptivity based on the gene expression status of uterine biopsy sample cells. Guidance can significantly improve the success rate of in vitro fertilization or embryo implantation.